Nalbuphine versus Magnesium Sulfate as an Adjuvant in Ultrasound Infraclavicular Brachial Plexus Block: Efficacy and Postoperative Outcomes

Nalbuphine versus Magnesium Sulfate as an Adjuvant in Infraclavicular Brachial Plexus Block - Infraclav, MgSo4,Nalbu,

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000038854

Enrollment

Registered

2020-12-09

Start date

2020-02-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adjuvants to local anesthetics in infraclavicular block

Interventions

Group N where nalbuphine 20mg in 2ml added to 25ml bupivacaine 0.5%% (total volume 27 ml) Group M as 150mg magnesium sulfate was added to 25ml bupivacaine 0.5% % (total volume 27 ml).

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: After approval from the local ethical committee anesthesia department menoufia university Egypt, and patients informed consent, 60 adult patients aged from 20-60 years with ASA physical status classes I and II, scheduled for elective surgery in hands, wrist, and forearm.

Exclusion criteria

Exclusion criteria: patient refusal, or uncooperative patients, patient on anticoagulant therapy evidence of sever pulmonary, hepatic or renal disease, body mass index more than 35kg/m2,and history of brachial plexus injury and allergy to any of the drugs that will be used in the study.

Design outcomes

Primary

Measure	Time frame
Assess the effect of nalbuphine and magnesium sulfate as an adjuvant to bupivacaine on onset and duration of motor and sensory infraclavicular block.	—

Countries

Africa

Contacts

Public ContactWafiya Mahdy

Menofia University Anesthesia department

wafia.mahdi@med.menofia.edu.eg00201094245826

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026